Expressing Recombinant Lymphokine, Interferon, Hormone, Growth Factor Or Morphogen Patents (Class 435/365.1)
-
Patent number: 9603949Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays. Accordingly, in certain embodiments, the present invention provides a probe for detecting a microbial endonuclease comprising a substrate oligonucleotide of 2-30 nucleotides in length, a fluorescence-reporter group operably linked to the oligonucleotide, and a fluorescence-quencher group operably linked to the oligonucleotide. The fluorescence-reporter group and the fluorescence-quencher group are separated by at least one RNAse-cleavable residue, e.g., RNA base.Type: GrantFiled: August 30, 2012Date of Patent: March 28, 2017Assignees: University of Iowa Research Foundation, Integrated DNA Technologies, Inc.Inventors: James O. McNamara, II, Katie R. Stockdale, Lingyan Huang, Alexander R. Horswill, Mark A. Behlke, Frank J. Hernandez
-
Patent number: 9220757Abstract: The present invention relates to an implantable composition for treating a damaged tissue and a method for inducing an in vivo migration of a cell for treatment to a damaged tissue region. The present invention treats the damaged tissue by inducing/promoting homing of a cell for tissue generation by implanting a biodegradable scaffold reacted with chemotactic factors (for example, IL-8 or MIP-3?) to a damaged location (for example, joint cartilage or skin). Thus, the composition of the present invention can not only be applied to the treatment of a damaged bone tissue, a joint cartilage, or a skin tissue more conveniently and efficiently compared to the conventional technology, but can also be used as a useful treatment supplement agent in cell treatment using allogeneic cell by enabling efficient utilization of cell resources for treatment, the cell resources which are high in scarcity.Type: GrantFiled: January 26, 2012Date of Patent: December 29, 2015Assignee: Tego Science Inc.Inventors: Jin Woo Lee, Min Sung Park, Yun Hee Kim
-
Publication number: 20150072932Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.Type: ApplicationFiled: April 9, 2013Publication date: March 12, 2015Inventors: Geraldine Siegfried, Abdel-Majid Khatib
-
Publication number: 20150064157Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20150064185Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: ApplicationFiled: November 13, 2014Publication date: March 5, 2015Inventors: Lucy J. HOLT, Ian M. Tomlinson
-
Patent number: 8932828Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.Type: GrantFiled: September 29, 2010Date of Patent: January 13, 2015Assignee: Bolder Biotechnology, Inc.Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
-
Publication number: 20140323401Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.Type: ApplicationFiled: April 8, 2014Publication date: October 30, 2014Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
-
Publication number: 20140256621Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: July 3, 2012Publication date: September 11, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
-
Publication number: 20140235535Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.Type: ApplicationFiled: July 3, 2012Publication date: August 21, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
-
Publication number: 20140206758Abstract: The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.Type: ApplicationFiled: April 3, 2014Publication date: July 24, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Barbara K. Felber, George N. Pavlakis
-
Patent number: 8772027Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.Type: GrantFiled: March 13, 2013Date of Patent: July 8, 2014Assignee: Bayer Pharmaceuticals CorporationInventors: Sham-Yuen Chan, Hsinyi Yvette Tang, Yiwen Tao, Yongjian Wu, Ruth Kelly
-
Patent number: 8759090Abstract: Disclosed herein are methods for producing a stem cell bank and providing stem cell samples for purchase or use. Also, provided herein are embodiments relating to a stem cell bank and stem cell banking system.Type: GrantFiled: October 30, 2006Date of Patent: June 24, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: Kiminobu Sugaya, Angel Alvarez
-
Publication number: 20140171625Abstract: The invention provides novel polypeptides having at least one biological activity of cardiotrophin and improved biologic drug-like properties, and polynucleotides encoding the polypeptides of the invention. The polypeptides of the invention can be used therapeutically, such as, for example, in methods of tissue regeneration.Type: ApplicationFiled: February 1, 2012Publication date: June 19, 2014Applicant: Fate Therapeutics, Inc.Inventors: Tom Tong Lee, Kevin Lai, John Mendlein, Peter Flynn
-
Publication number: 20140165223Abstract: Described are methods and compositions for inhibiting the trimerization of ligands belonging to the TNF superfamily, in particular, inhibiting RANKL trimerization. Accordingly, the methods and compositions provided herein can be used to treat disorders associated with increased RANK signaling, in particular those related to bone loss. Compounds that inhibit trimerization of ligands belonging to the TNF superfamily are also described.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: B.S.R.C. "Alexander Fleming"Inventors: Eleni Ntouni, Georgios Kollias
-
Publication number: 20140154214Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: ApplicationFiled: February 4, 2014Publication date: June 5, 2014Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Publication number: 20140148390Abstract: The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides.Type: ApplicationFiled: July 4, 2012Publication date: May 29, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Haupts, Andreas Wilmen
-
Publication number: 20140142046Abstract: The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.Type: ApplicationFiled: January 11, 2012Publication date: May 22, 2014Applicant: FATE THERAPEUTICS, INC.Inventors: Tom Tong Lee, Monica Hayhurst Bennett, Michael J. Fitch, Peter Flynn
-
Publication number: 20140121153Abstract: The present invention relates to an isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 21; or (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 21, and to therapeutic treatments based thereon.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Inventors: Tamara SANDLER, Orly DEVARY
-
Publication number: 20140105896Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140105855Abstract: IL-17 Receptor binding proteins, including non-naturally occurring and recombinantly modified proteins, methods of making and using such molecules as therapeutic, prophylactic and diagnostic agents are provided.Type: ApplicationFiled: April 6, 2012Publication date: April 17, 2014Inventor: Kenan Christopher Garcia
-
Publication number: 20140005109Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.Type: ApplicationFiled: January 13, 2012Publication date: January 2, 2014Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Tonia S. Rex, Timothy A. Sullivan
-
Publication number: 20130336924Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Inventors: JUAN ALVAREZ, JEAN CHAMOUN
-
Publication number: 20130336926Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.Type: ApplicationFiled: June 11, 2013Publication date: December 19, 2013Applicant: Amgen Inc.Inventors: John E. SIMS, Blair R. RENSHAW, Christopher GABEL, Jennifer E. TOWNE, Randal R. KETCHEM
-
Publication number: 20130316404Abstract: The present invention relates to a polypeptide having interleukin-10 function, comprising two interleukin-10 monomer subunits covalently linked by a linker. The present invention further relates to a nucleic acid molecule encoding the polypeptide of the invention, a vector comprising said nucleic acid molecule, a non-human host transformed with the nucleic acid molecule or the vector of the invention as well as a method for the production of a recombinant polypeptide of the invention. The present invention further relates to a pharmaceutical composition as well as to the polypeptide, the nucleic acid molecule, the vector or the host or host cell of the invention for use in treating and/or preventing inflammatory diseases.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicants: THE UNIVERSITY OF MANCHESTER, TECHNISCHE UNIVERSITÄT DRESDENInventors: Axel Roers, Sebastian Lanvermann, Werner Müller
-
Publication number: 20130196909Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130196910Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130164251Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.Type: ApplicationFiled: June 30, 2010Publication date: June 27, 2013Inventors: Xiaofang Wen, Yiliang Wu, Yefei Wang, Zhiyu Yang, Min Fan, Yujiao Wang, Xiaochun Fang, You Lu
-
Publication number: 20130143949Abstract: A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone.Type: ApplicationFiled: May 1, 2012Publication date: June 6, 2013Applicants: NATIONAL INSTITUTE OF HEALTHInventors: Wei-Chiang SHEN, Yun BAI, David ANN, Adam WIDER
-
Patent number: 8409857Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.Type: GrantFiled: May 4, 2012Date of Patent: April 2, 2013Assignee: Bayer Pharmaceuticals CorporationInventors: Sham-Yuen Chan, Hsinyi Yvette Tang, Yiwen Tao, Yongjian Wu, Ruth Kelly
-
Patent number: 8399219Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: February 23, 2010Date of Patent: March 19, 2013Assignee: Cytomx Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
-
Patent number: 8383788Abstract: A nucleotide molecule encoding a protein encoded by a Fos regulated gene or a fragment thereof, wherein said protein or fragment thereof is encoded by any one of the nucleotide sequences shown in FIG. 1 or 2 or a fragment thereof, including allelic variants and species variants of the nucleotide sequences.Type: GrantFiled: May 7, 2002Date of Patent: February 26, 2013Assignee: Vegenics Pty LimitedInventor: Salvatore Oliviero
-
Publication number: 20130023477Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Inventors: Richard Ross, Peter Artymiuk, Jon Sayers
-
Publication number: 20120322735Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.Type: ApplicationFiled: August 22, 2012Publication date: December 20, 2012Inventors: Peter Artymiuk, Richard A. Ross, Jon Sayers
-
Patent number: 8329429Abstract: The present invention provides a method of enhanced protein production that comprises the step of expressing a recombinant gene encoding the protein in eukaryotic cells under conditions in which cleavage of the pro-domain of the protein is inhibited or eliminated. Generally the method of the present invention includes the step of inhibiting or altering the cleavage of a pro-domain of a recombinant protein of interest in order to increase the amount of recombinant protein secreted from a eukaryotic cell. Recombinant proteins that can be prepared using the method of this invention include members of the transforming growth factor-? (TGF-?) superfamily, such as bone morphogenetic proteins. Also provided are genetically engineered cells and polynucleotides for performing the method of the invention.Type: GrantFiled: November 25, 2009Date of Patent: December 11, 2012Assignee: Induce Biologics Inc.Inventors: Sean A. F. Peel, Cameron M. L. Clokie, Jeffrey D. Turner
-
Patent number: 8318457Abstract: The present invention relates to nucleic acid molecules comprising a nucleic acid sequence coding for the ?- and the ?-chain of the human follicle stimulating hormone (FSH), respectively, which has been modified with respect to the codon usage in CHO cells. The present invention further relates to a recombinant nucleic acid molecule comprising such nucleic acid sequences and host cells containing such recombinant nucleic acid molecules, as well as their use in the production of recombinant human FSH. Finally, the present invention also relates to a method for producing host cells expressing human follicle stimulating hormone by transfecting cells in suspension culture under serum-free conditions with the recombinant nucleic acid molecule of the present invention.Type: GrantFiled: June 27, 2008Date of Patent: November 27, 2012Assignee: BioGeneriX AGInventors: Stefan Arnold, Nanni Jelinek
-
Publication number: 20120238620Abstract: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide that encodes a polypeptide of SEQ ID NO:12, and a polynucleotide that encodes a fragment of the polypeptide of SEQ ID NO:12; and wherein the nucleic acid does not encode for the amino acid sequence of amino acids 71-93 of SEQ ID NO:1. Pharmaceutical compositions, vectors, and methods for inhibiting neovascularization or angiogenesis comprising or utilizing the nucleic acids also are provided.Type: ApplicationFiled: September 12, 2011Publication date: September 20, 2012Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
-
Publication number: 20120204281Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 9, 2012Inventors: Clifford J. WOOLF, Tarek A. Samad
-
Publication number: 20120204280Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 9, 2012Inventors: Clifford J. Woolf, Tarek A. Samad
-
Publication number: 20120082996Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.Type: ApplicationFiled: September 19, 2011Publication date: April 5, 2012Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
-
Publication number: 20110294733Abstract: The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.Type: ApplicationFiled: January 20, 2010Publication date: December 1, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Jae Kap Jeong, Sung Yul Lee, Yeon Jung Song, Won Jo Shim
-
Publication number: 20110287480Abstract: The invention relates to novel neurogenin proteins, nucleic acids and antibodies.Type: ApplicationFiled: November 8, 2010Publication date: November 24, 2011Inventors: David J. Anderson, Qiufa Ma, Lukas Sommer
-
Publication number: 20110287483Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Inventors: Christopher K. CROWELL, Gustavo E. GRAMPP
-
Patent number: 8012464Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: October 30, 2007Date of Patent: September 6, 2011Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner
-
Patent number: 7968684Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: November 12, 2004Date of Patent: June 28, 2011Assignee: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20100311162Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: ApplicationFiled: June 21, 2010Publication date: December 9, 2010Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Patent number: 7847079Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: May 8, 2006Date of Patent: December 7, 2010Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 7750133Abstract: This invention discloses two new VEGI isoforms named VEGI-192a and VEGI-192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-174 and VEGI-251. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.Type: GrantFiled: December 6, 2007Date of Patent: July 6, 2010Assignee: Georgetown UniversityInventors: Luyuan Li, Hongguang Pan
-
Patent number: 7629168Abstract: A reversibly immortalized human pancreatic islet cell line containing an hTERT gene and an SV40T gene each interposed between a pair of LoxP sequences, characterized in that it is capable of producing insulin and enhancing expression of insulin after excising the hTERT gene and the SV40T gene, in particular, NAKT-13 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Sep. 4, 2003, accession number: FERM BP-08461) or a passage cell line thereof; a human pancreatic islet cell obtained by excising the hTERT gene and the SV40T gene from the reversibly immortalized human pancreatic islet cell line or passage cell line thereof; and use of these cells. By using the reversibly immortalized human pancreatic islet cell line of the invention insulin-producing cells can be easily and surely obtained in a number enough to meet the demand.Type: GrantFiled: November 10, 2003Date of Patent: December 8, 2009Assignees: Kuraray Medical Inc.Inventors: Noriaki Tanaka, Naoya Kobayashi, Michiki Narushima, Yoshihito Tanaka
-
Patent number: 7601342Abstract: The invention is concerned with fusions of dendritic cells and antigen presenting cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy. The fusions according to the invention can also be used in methods for antigen discovery.Type: GrantFiled: January 24, 2007Date of Patent: October 13, 2009Assignee: Dana Farber Cancer InstituteInventors: Jianlin Gong, Donald Kufe
-
Patent number: 7569384Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: August 8, 2006Date of Patent: August 4, 2009Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben